Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Buys 8,305 Shares of Company Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par purchased 8,305 shares of Lycia Therapeutics stock in a transaction on Monday, November 2nd. The shares were acquired at an average cost of $26.95 per share, with a total value of $223,819.75. Following the completion of the transaction, the insider directly owned 6,858,542 shares in the company, valued at $184,837,706.90. The trade was a 0.12% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par bought 9,004 shares of Lycia Therapeutics stock. The shares were acquired at an average cost of $26.28 per share, with a total value of $236,625.12.
• On Thursday, October 29th, Venrock Healthcare Capital Par bought 1,000 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $26.33 per share, with a total value of $26,330.00.
• On Wednesday, October 28th, Venrock Healthcare Capital Par purchased 15,000 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $25.45 per share, for a total transaction of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par purchased 39,796 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par purchased 1,952,705 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $18.04 per share, for a total transaction of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par purchased 52,939 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $25.91 per share, for a total transaction of $1,371,649.49.

Lycia Therapeutics Stock Up 4.8%

NASDAQ LYCA opened at $28.92 on Thursday. Lycia Therapeutics, Inc. has a fifty-two week low of $22.19 and a fifty-two week high of $36.49.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st.

Lycia Therapeutics Company Profile

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.